BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29755703)

  • 21. The epidemiology and risk factor of carbapenem-resistant enterobacteriaceae colonization and infections: Case control study in a single institute in Japan.
    Asai N; Sakanashi D; Suematsu H; Kato H; Hagihara M; Nishiyama N; Koizumi Y; Yamagishi Y; Mikamo H
    J Infect Chemother; 2018 Jul; 24(7):505-509. PubMed ID: 29548627
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Carbapenem-resistant Enterobacteriaceae: A retrospective review of treatment and outcomes in a long-term acute care hospital.
    Igbinosa O; Dogho P; Osadiaye N
    Am J Infect Control; 2020 Jan; 48(1):7-12. PubMed ID: 31431290
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for colonization due to carbapenem-resistant Enterobacteriaceae among patients exposed to long-term acute care and acute care facilities.
    Bhargava A; Hayakawa K; Silverman E; Haider S; Alluri KC; Datla S; Diviti S; Kuchipudi V; Muppavarapu KS; Lephart PR; Marchaim D; Kaye KS
    Infect Control Hosp Epidemiol; 2014 Apr; 35(4):398-405. PubMed ID: 24602945
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for mortality among carbapenem-resistant enterobacteriaceae carriers with focus on immunosuppression.
    Bar-Yoseph H; Cohen N; Korytny A; Andrawus ER; Even Dar R; Geffen Y; Hussein K; Paul M
    J Infect; 2019 Feb; 78(2):101-105. PubMed ID: 30312647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tandem fecal microbiota transplantation cycles in an allogeneic hematopoietic stem cell transplant recipient targeting carbapenem-resistant Enterobacteriaceae colonization: a case report and literature review.
    Su F; Luo Y; Yu J; Shi J; Zhao Y; Yan M; Huang H; Tan Y
    Eur J Med Res; 2021 Apr; 26(1):37. PubMed ID: 33910622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections.
    Bartoletti M; Tedeschi S; Pascale R; Raumer L; Maraolo AE; Palmiero G; Tumietto F; Cristini F; Ambretti S; Giannella M; Lewis RE; Viale P
    Int J Antimicrob Agents; 2018 Mar; 51(3):516-521. PubMed ID: 29410250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors Associated to Prevalence and Incidence of Carbapenem-Resistant Enterobacteriaceae Fecal Carriage: A Cohort Study in a Mexican Tertiary Care Hospital.
    Torres-Gonzalez P; Cervera-Hernandez ME; Niembro-Ortega MD; Leal-Vega F; Cruz-Hervert LP; García-García L; Galindo-Fraga A; Martinez-Gamboa A; Bobadilla-Del Valle M; Sifuentes-Osornio J; Ponce-de-Leon A
    PLoS One; 2015; 10(10):e0139883. PubMed ID: 26431402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk Factors and Molecular Epidemiology of Complicated Intra-Abdominal Infections With Carbapenem-Resistant Enterobacteriaceae: A Multicenter Study in China.
    Liu J; Zhang L; Pan J; Huang M; Li Y; Zhang H; Wang R; Zhao M; Li B; Liu L; Gong Y; Bian J; Li X; Tang Y; Lei M; Chen D
    J Infect Dis; 2020 Mar; 221(Suppl 2):S156-S163. PubMed ID: 32176797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of carbapenem resistance on outcomes of bloodstream infection caused by Enterobacteriaceae in low-income and middle-income countries (PANORAMA): a multinational prospective cohort study.
    Stewardson AJ; Marimuthu K; Sengupta S; Allignol A; El-Bouseary M; Carvalho MJ; Hassan B; Delgado-Ramirez MA; Arora A; Bagga R; Owusu-Ofori AK; Ovosi JO; Aliyu S; Saad H; Kanj SS; Khanal B; Bhattarai B; Saha SK; Uddin J; Barman P; Sharma L; El-Banna T; Zahra R; Saleemi MA; Kaur A; Iregbu K; Uwaezuoke NS; Abi Hanna P; Feghali R; Correa AL; Munera MI; Le TAT; Tran TTN; Phukan C; Phukan C; Valderrama-Beltrán SL; Alvarez-Moreno C; Walsh TR; Harbarth S
    Lancet Infect Dis; 2019 Jun; 19(6):601-610. PubMed ID: 31047852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clearance of carbapenem-resistant Enterobacteriaceae vs vancomycin-resistant enterococci carriage after faecal microbiota transplant: a prospective comparative study.
    Dinh A; Fessi H; Duran C; Batista R; Michelon H; Bouchand F; Lepeule R; Vittecoq D; Escaut L; Sobhani I; Lawrence C; Chast F; Ronco P; Davido B
    J Hosp Infect; 2018 Aug; 99(4):481-486. PubMed ID: 29477634
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Impact of Modifying Empirical Antibiotic Therapy Based on Intestinal Colonization Status on Clinical Outcomes of Febrile Neutropenic Patients.
    Alrstom A; Alsuliman T; Daher N; Abouharb R
    Infect Chemother; 2021 Mar; 53(1):63-74. PubMed ID: 33538132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of ceftazidime-avibactam in the treatment of infections due to Carbapenem-resistant Enterobacteriaceae.
    Alraddadi BM; Saeedi M; Qutub M; Alshukairi A; Hassanien A; Wali G
    BMC Infect Dis; 2019 Sep; 19(1):772. PubMed ID: 31484510
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology and risk factors of neurosurgical bacterial meningitis/encephalitis induced by carbapenem resistant Enterobacteriaceae.
    Guanghui Z; Jing L; Guojun Z; Hong L
    J Infect Chemother; 2020 Jan; 26(1):101-106. PubMed ID: 31445817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Factors associated to prevalence and treatment of carbapenem-resistant Enterobacteriaceae infections: a seven years retrospective study in three tertiary care hospitals.
    Pang F; Jia XQ; Zhao QG; Zhang Y
    Ann Clin Microbiol Antimicrob; 2018 Mar; 17(1):13. PubMed ID: 29571291
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk factors and outcomes of patients colonized with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant
    Kassem A; Raed A; Michael T; Sagi O; Shimoni O; Borer A; Saidel-Odes L
    Infect Control Hosp Epidemiol; 2020 Oct; 41(10):1154-1161. PubMed ID: 32624034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis.
    Zilberberg MD; Nathanson BH; Sulham K; Fan W; Shorr AF
    BMC Infect Dis; 2017 Apr; 17(1):279. PubMed ID: 28415969
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictors for gut colonization of carbapenem-resistant Enterobacteriaceae in neonates in a neonatal intensive care unit.
    Singh NP; Choudhury DD; Gupta K; Rai S; Batra P; Manchanda V; Saha R; Kaur IR
    Am J Infect Control; 2018 Jun; 46(6):e31-e35. PubMed ID: 29803234
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fecal carriage of carbapenem-resistant
    Mohan B; Prasad A; Kaur H; Hallur V; Gautam N; Taneja N
    Indian J Med Microbiol; 2017; 35(4):555-562. PubMed ID: 29405149
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vital signs: carbapenem-resistant Enterobacteriaceae.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2013 Mar; 62(9):165-70. PubMed ID: 23466435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of antibiotic de-escalation on clinical outcomes in patients with carbapenem-resistant Enterobacteriaceae bacteremia (CRE) in the hematology-oncology setting.
    Bansal N; Sachdeva N; Bhurani D; Agarwal N; Ahmed R; Mehta P; Halder R
    Germs; 2023 Sep; 13(3):221-228. PubMed ID: 38146379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.